Pneumocystis carinii pneumonia prophylaxis and early clinical manifestations of severe perinatal human immunodeficiency virus type 1 infection

Pediatric Infectious Disease Journal

Volumn 17, Issue 5, 1998, Pages 398-402

  Maldonado, Yvonne A ^a   Araneta, Rosario G ^a,b   Hersh, Adam L ^a,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Acquired immunodeficiency syndrome; Perinatal human immunodeficiency virus; Pneumocystis carinii pneumonia prophylaxis

Indexed keywords

COTRIMOXAZOLE; ZIDOVUDINE;

ADOLESCENT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BRAIN DISEASE; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT VIRUS INFECTION; MAJOR CLINICAL STUDY; OPPORTUNISTIC INFECTION; PERINATAL MORBIDITY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SEROPREVALENCE; SURVIVAL TIME; WASTING SYNDROME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HIV-1; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; PNEUMONIA, PNEUMOCYSTIS; RETROSPECTIVE STUDIES; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; ZIDOVUDINE;

EID: 0031780376     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199805000-00010     Document Type: Article

References (24)

1. Blanche S, Tardieu M, Duliege AM, et al. Longitudinal study of 94 HIV symptomatic infants with materno-foetal HIV infection: evidence for a bimodal expression of clinical and biologic symptoms. Am J Dis Child 1990;144:1210-5.
2. Duliege AM, Messiah A, Blanche S, Tardieu M, Griscelli C, Spira A. Natural history of human immunodeficiency virus type 1 infection in children: prognostic value of laboratory tests on the bimodal progression of disease. Pediatr Infect Dis J 1992;11:630-5.
3. Galli L, de Martino M, Tovo PA, et al. Onset of clinical signs in children with HIV-1 perinatal infection: Italian Register for HIV Infection in Children. AIDS 1995;9:455-61.
4. Auger I, Thomas P, De Gruttola V. Incubation periods for paediatric AIDS patients. Nature 1988;336:575-7.
5. MaWhinney S, Pagano M, Thomas P. Age at AIDS diagnosis for children with perinatally acquired HIV. J AIDS 1993;6: 1139-44.
6. Dickover RE, Dillon M, Gillette SG, et al. Rapid increases in load of human immunodeficiency virus correlate with early disease progression and loss of CD4 cells in vertically infected infants. J Infect Dis 1994;170:1279-84.
7. Simonds RJ, Oxtoby MJ, Caldwell MB, Gwinn ML, Rogers MF. Pneumocystis carinii pneumonia among US children with perinatally acquired HIV infection. JAMA 1993;270: 470-3.
8. Chu SY, Buehler JW, Oxtoby MJ, Kilbourne BW. Impact of the human immunodeficiency virus epidemic on mortality in children, United States. Pediatrics 1991;87:806-10.
9. Simonds RJ, Lindegren ML, Thomas P, et al. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. N Engl J Med 1995;332:786-90.
10. Bozzette SA, Finkelstein DM, Spector SA. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995;332:693-9.
11. Rigaud M, Pollack H, Leibovitz E. Efficacy of primary chemoprophylaxis against Pneumocystis carinii pneumonia during the first year of life in infants infected with human immunodeficiency virus type 1. J Pediatr 1994;125:476-80.
12. Thea DM, Lambert G, Weedon J, et al. Benefit of primary prophylaxis before 18 months of age in reducing the incidence of Pneumocystis carinii pneumonia and early death in a cohort of 112 human immunodeficiency virus-infected infants. Pediatrics 1996;97:59-64.
13. Hoover DR, Saah AJ, Bacellar H, et al. Clinical manifestations of AIDS in the era of Pneumocystis prophylaxis. N Engl J Med 1993;329:1922-6.
14. Maldonado YA, Wang NE, Caldwell B, et al. Factors associated with early clinical recognition of children with perinatal human immunodeficiency virus infection. J Infect Dis 1995; 171:689-92.
15. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age; official authorized addenda: human immunodeficiency virus infection codes and official guidelines for coding and reporting ICD-9-CM. MMWR 1994;43(RR-12):1-17.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958;53:457.
17. Sperling RS, Shapiro De, Coombs, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1996;335:1621-9.
18. Mofenson LM, Korelitz J, Meyer WA III, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. J Infect Dis 1997; 175:1029-38.
19. Barnhart HX, Caldwell MB, Thomas P, et al. Natural history of HIV disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease Project. Pediatrics 1996;97:710-6.
20. European Collaborative Study. Natural history of vertically acquired human immunodeficiency virus-1 infection. Pediatrics 1994;94:815-9.
21. Pizzo PA, Wilfert C. Antiretroviral therapy for infection due to human immunodeficiency virus in children. Clin Infect Dis 1994;19:177-96.
22. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Co-ordinating Committee. Lancet 1997;349(9058):1086-92.
23. Hammer SM. Advances in antiretroviral therapy and viral load monitoring. AIDS 1996;10(Suppl 3):S1-11.
24. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996;334:1011-7.